Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
† Study has passed its completion date and status has not been verified in more than two years.